Connect Biopharma

Connect Biopharma company information, Employees & Contact Information

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research. Our lead product candidate, CBP-201 — an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) — has been in clinical trials for the treatment of AD, asthma, and CRSwNP. Our second lead product candidate, CBP-307 — a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1) — has been in clinical trials for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD). Furthermore, we have started the clinical development of an additional product candidate, CBP-174 — a peripherally acting antagonist of histamine receptor 3 — for the treatment of pruritus associated with AD. With clinical development activities in the United States, China, Europe, and Australia, and operations in those geographies as well as Hong Kong, Connect Biopharma is building a rich global pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. For additional information about Connect Biopharma, please visit our website at www.connectbiopharm.com

Company Details

Employees
38
Founded
-
Address
12265 El Camino Real,
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Diego, California
Looking for a particular Connect Biopharma employee's phone or email?

Connect Biopharma Questions

News

Connect Biopharma to Present Latest Inflammatory Disease Developments at BTIG Conference - Stock Titan

Connect Biopharma to Present Latest Inflammatory Disease Developments at BTIG Conference Stock Titan

Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire

Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire

Connect Biopharma Unveils Positive Data from Global Phase 2 Asthma Trial of Rademikibart - citybiz

Connect Biopharma Unveils Positive Data from Global Phase 2 Asthma Trial of Rademikibart citybiz

Connect Biopharma Announces Plans to Terminate its American - GlobeNewswire

Connect Biopharma Announces Plans to Terminate its American GlobeNewswire

Connect Bio Eyeing Commercial Partner for Inflammatory Disease Treatment - San Diego Business Journal

Connect Bio Eyeing Commercial Partner for Inflammatory Disease Treatment San Diego Business Journal

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors - GlobeNewswire

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors GlobeNewswire

Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China - GlobeNewswire

Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China GlobeNewswire

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD - GlobeNewswire

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD GlobeNewswire

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewswire

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement GlobeNewswire

Top Connect Biopharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant